Hendrik Bernardus van der Worp

Hendrik Bernardus van der Worp

Auto-generated profile, based on publicly available information

Hendrik Bernardus van der Worp

Department of Neurology and Neurosurgery, Brain Center, University Medical Center Utrecht, the Netherlands (H.B.v.d.W.).

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2010 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
HWH. Bart van der Worp
H. Bart van der Worp
DHDavid W. Howells
David W. Howells
ESEmily S. Sena
Emily S. Sena
MPMichelle J. Porritt
Michelle J. Porritt
SRSarah Rewell
Sarah Rewell
MMMalcolm R. Macleod
Malcolm R. Macleod
H. Bart van der Worp and colleagues discuss the controversies and possibilities of translating the results of animal experiments into human clinical trials.

3 May 2007 in Brain
Verified
Journal Article
Open access
PDF file
HWH. Bart van der Worp
H. Bart van der Worp
ESEmily S. Sena
Emily S. Sena
GDGeoffrey Donnan
Geoffrey Donnan
DHDavid W. Howells
David W. Howells
MMMalcolm R. Macleod
Malcolm R. Macleod
Induced hypothermia is proposed as a treatment for acute ischaemic stroke, but there have been too few clinical trials involving too few patients to draw any conclusions about the therapeutic benefit of cooling. Animal studies of induced hypothermia in focal cerebral ischaemia have tested cooling throughout a wide range of target temperatures, durations and intervals between stroke onset and the initiation of hypothermia. These studies, therefore, provide an opportunity to evaluate the effectiveness of different treatment strategies in animal models to inform the design of future clinical trials. We performed a systematic review and meta-analysis of the evidence for efficacy of hypothermia in animal models of ischaemic stroke, and identified 101 publications reporting the effect of hypothermia on infarct size or functional outcome, including data from a total of 3353 animals. Overall, hypothermia reduced infarct size by 44% [95% confidence interval (CI), 40–47%]. Efficacy was highest with cooling to lower temperatures (≤31°C), where treatment was started before or at the onset of ischaemia and in temporary rather than permanent ischaemia models. However, a substantial reduction in infarct volume was also observed with cooling to 35°C (30%; 95% CI, 21–39%), with initiation of treatment between 90 and 180 min (37%; 95% CI, 28–46%) and in permanent ischaemia models (37%; 95% CI, 30–43%). The effects of hypothermia on functional outcome were broadly similar. We conclude that in animal models of focal cerebral ischaemia, hypothermia improves outcome by about one-third under conditions that may be achievable for large numbers of patients with ischaemic stroke. Large randomized clinical trials testing the effect of hypothermia in patients with acute ischaemic stroke are warranted.

9 August 2007 in New England Journal of Medicine
Verified
Journal Article
Closed access
HWH. Bart van der Worp
H. Bart van der Worp
JGJan van Gijn
Jan van Gijn
A 62-year-old man has sudden weakness of the left arm and leg and slurred speech. Except for untreated hypertension, his medical history is unremarkable. He is a current smoker with a smoking history of 45 pack-years. On arrival at the emergency department 1 hour 15 minutes after the onset of symptoms, he reports no headache or vomiting. His blood pressure is 180/100 mm Hg; his pulse is 76 beats per minute and is regular. How should this patient be evaluated and treated in the short term?

15 May 2014 in International Journal of Stroke
Verified
Journal Article
Closed access
HWH. Bart van der Worp
H. Bart van der Worp
MMMalcolm R. Macleod
Malcolm R. Macleod
PBPhilip M. W. Bath
Philip M. W. Bath
JDJacques Demotes
Jacques Demotes
IDIsabelle Durand-Zaleski
Isabelle Durand-Zaleski
SSStefan Schwab
Stefan Schwab

1 October 2022 in Stroke
Verified
Journal Article
Closed access
PDF file
SVSimone M. Uniken Venema
Simone M. Uniken Venema
JDJan Willem Dankbaar
Jan Willem Dankbaar
ALAad van der Lugt
Aad van der Lugt
DDDiederik WJ Dippel
Diederik WJ Dippel
HWH. Bart van der Worp
H. Bart van der Worp
Clinical outcomes of patients with acute ischemic stroke depend in part on the extent of their collateral circulation. A good collateral circulation has also been associated with greater benefit of intravenous thrombolysis and endovascular treatment. Treatment decisions for these reperfusion therapies are increasingly guided by a combination of clinical and imaging parameters, particularly in later time windows. Computed tomography and magnetic resonance imaging enable a rapid assessment of both the collateral extent and cerebral perfusion. Yet, the role of the collateral circulation in clinical decision-making is currently limited and may be underappreciated due to the use of rather coarse and rater-dependent grading methods. In this review, we discuss determinants of the collateral circulation in patients with acute ischemic stroke, report on commonly used and emerging neuroimaging techniques for assessing the collateral circulation, and discuss the therapeutic and prognostic implications of the collateral circulation in relation to reperfusion therapies for acute ischemic stroke.

16 October 2017 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
MJMarit de Jong
Marit de Jong
HWH. Bart van der Worp
H. Bart van der Worp
YGYolanda van der Graaf
Yolanda van der Graaf
FVFrank L. J. Visseren
Frank L. J. Visseren
JWJan Westerink
Jan Westerink
Pioglitazone targets multiple pathogenic pathways involved in the development of cardiovascular diseases (CVD). The aim of this systematic review and meta-analysis is to assess the effects of pioglitazone treatment on the secondary prevention of CVD. Randomized-controlled trials of pioglitazone in patients with CVD were identified through PubMed, Embase, Cochrane and CINAHL, in a search up to May 2016. Studies were included if pioglitazone was compared with any control (usual care, placebo or active comparator) and if patients were previously diagnosed with CVD. The outcomes of interest included major adverse cardiovascular events (MACE), myocardial infarction (MI), stroke, all-cause mortality and heart failure (HF). All outcomes were compared by pooled risk ratios (RR) with a 95% confidence interval (CI). Pooled estimates were calculated using a random-effects model. Ten studies reported the effects of pioglitazone on any of the outcomes of interest. Pioglitazone reduced recurrent MACE (RR 0.74, 95% 0.60–0.92; I2 = 35), MI (RR 0.77, 95% CI 0.64–0.93; I2 = 0%), or stroke (RR 0.81, 95% CI 0.68–0.96; I2 = 0%). Pioglitazone did not reduce all-cause mortality (RR 0.94, 95% CI 0.81–1.08; I2 = 0%), whereas pioglitazone treatment was associated with an increased risk of HF (RR 1.33, 95% CI 1.14–1.54). Pioglitazone lowers the risk of recurrent MACE, stroke, or MI in patients with clinical manifest vascular disease. Pioglitazone does not lower the risk for all-cause mortality, and increases the risk for the development of HF.